StreetInsider.com News Articles

Sangamo picks Lilly and PTC as buyers in bankruptcy auction

Wed, 12 Aug 2026 16:01:43 -0400

Sangamo Therapeutics (OTCID Basic Market: SGMOQ) has selected winning bidders in a court-supervised auction under Section 363 of the U.S. Bankruptcy Code, yielding approximately $163.55 million in cash at closing and up to $100 million in potential future milestone payments, according to a press release.

PTC Therapeutics was selected as the winning bidder for Sangamo's Fabry disease program, isaralgagene civaparvovec (ST-920), for $111 million in cash at closing. The deal includes up to $100 million in potential milestone payments: $80 million upon receiving accelerated FDA approval and $20 million upon full or traditional FDA approval.

Eli Lilly and Company was selected to

Sangamo picks Lilly and PTC as buyers in bankruptcy auction

Wed, 12 Aug 2026 16:01:43 -0400

Eli Lilly and Company was selected to

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

RICHMOND, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCID Basic Market: SGMOQ), a genomic medicine company, today announced that it has successfully concluded a court-supervised auction process under Section 363 of the U.S. Bankruptcy Code to maximize the value of Sangamo’s assets for the benefit of all stakeholders.

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones

Wed, 12 Aug 2026 16:01:00 -0400

PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec

Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program

Proposed sales subject to final approval by U.S. Bankruptcy Court

Following a competitive

Form 8-K SANGAMO THERAPEUTICS, For: Jun 24

Wed, 01 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260701/26720478.html